Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer win is supposed to be the prize.
After years of R&D, regulatory navigation, and patent strategy, the “first” generic applicant often expects a clean runw…

Read the Clock Right: Mapping Regulatory Exclusivities for True Generic Drug Entry Timing
Generic drug competition is often described as a race—but in reality, it’s a calendar. And the calendar is governed by a patchwork of regulatory exclusivities tha…

Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…

Generic entry isn’t just a legal milestone—it’s a financial event that decides who gets paid, who gets blocked, and how quickly patients get access.
Here’s the part most people miss: the “patent war” doesn’t begin when a drug goes generic. It begins be…

Consumers don’t always pay more because they’re uninformed. Sometimes they pay more because the market has trained them to trust—especially in healthcare, where “cheap” can feel like “risky.”
That’s the core tension behind branded generics: a category …

AI is already “reading” your drug—before your competitors do. Here’s what that means for strategy.
In pharma, we’ve spent years optimizing for what’s known: trial results, label language, patent estates, exclusivity windows, and the slow grind of regul…

Most pharma teams don’t lose because they lack talent. They lose because they’re flying blind—specifically, blind to the intelligence gap that sits between “knowing the science” and “knowing the patent landscape.”
That gap is rarely obvious in day-to-d…

Two Systems, One Fight: How the Patent Dance and Orange Book Linkage Are Shaping the $400B Biologics War
Biologics are no longer a niche corner of pharma—they’re the battleground. With the global biologics market projected to reach roughly $400 billion…

Most teams don’t lose to competitors because they lack talent—they lose because they’re late.
In pharma, “late” can mean a year (or more) of avoidable margin leakage. It can mean launching into a market that’s already crowded. It can mean your pipeline…

The patent cliff isn’t a cliff anymore—it’s a battlefield.
For years, the story was simple: once a drug’s patent expired, generic competition arrived and prices fell. But the modern reality is messier—and more strategic. The “win” after patent expira…